MARKET

CUE

CUE

Cue Biopharma Inc
NASDAQ
25.39
-0.15
-0.59%
After Hours: 25.09 -0.3 -1.18% 17:11 06/26 EDT
OPEN
25.76
PREV CLOSE
25.54
HIGH
26.75
LOW
24.60
VOLUME
82.63K
TURNOVER
--
52 WEEK HIGH
41.42
52 WEEK LOW
4.971
MARKET CAP
102.72M
P/E (TTM)
-4.6009
1D
5D
1M
3M
1Y
5Y
1D
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga · 3d ago
Weekly Report: what happened at CUE last week (0615-0619)?
Weekly Report · 4d ago
Cue Biopharma files to sell 551,724 shares of common stock for holders
TipRanks · 06/18 20:11
Weekly Report: what happened at CUE last week (0608-0612)?
Weekly Report · 06/15 10:02
Cue Biopharma files initial beneficial ownership statement for VP, principal accounting officer Michael Meluzio
PUBT · 06/11 21:49
Cue Biopharma Chief Legal Compliance Officer Ray Sumita files initial beneficial ownership statement
PUBT · 06/11 21:48
Quant rating check: Top oncology peers as Nuvalent goes private in $10.6B deal with GSK
Seeking Alpha · 06/09 09:18
Cue Biopharma director Daniel A. Camardo files initial beneficial ownership statement
PUBT · 06/08 20:24
More
About CUE
Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company, developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body. Its proprietary platform, Immuno-STAT (Selective Targeting and Alteration of T cells) and biologics are designed to harness the curative potential of the body’s intrinsic immune system through the selective modulation of disease-specific T cells without the adverse effects of broad systemic immune modulation. Its lead programs include drug product candidates designed to: CUE-400 series (Autoimmune Diseases) enhance regulatory T cells (Tregs) with a novel mechanism to proliferate, generate Tregs, and restore immune balance (CUE-401 for autoimmune conditions);CUE-500 series (Targeted Cell Depletion) redirect antiviral T cells to target eliminate pathogenic cells (CUE-501 for autoimmune B cell depletion); and CUE-100 series (Oncology) selectively activate tumor-specific T cells.

Webull offers Cue Biopharma Inc stock information, including NASDAQ: CUE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CUE stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CUE stock methods without spending real money on the virtual paper trading platform.